Hillstream Biopharma Expanded Its Collaboration With Minotaur Therapeutics And Its License Agreement With OmniAb To Advance Next-generation Targeted Knob Biologics (Picobodies) Against HER3 And A New Undisclosed Oncology Target
Portfolio Pulse from Benzinga Newsdesk
Hillstream Biopharma has expanded its collaboration with Minotaur Therapeutics and its license agreement with OmniAb. The aim is to advance next-generation targeted Knob Biologics (Picobodies) against HER3 and a new undisclosed oncology target.
July 20, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hillstream Biopharma's expanded collaborations could potentially lead to advancements in oncology treatments, which may positively impact the company's stock in the short term.
The expansion of Hillstream Biopharma's collaborations with Minotaur Therapeutics and OmniAb indicates a strategic move to advance their oncology treatments. This could potentially lead to positive outcomes in their research and development, which may attract investor interest and positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100